Page last updated: 2024-08-04 07:42:30
pkh 26
Description
PKH 26: no further information available 8/91 [MeSH]
Cross-References
| ID Source | ID |
|---|
| PubMed CID | 162642097 |
| MeSH ID | M0191029 |
Synonyms (5)
| Synonym |
|---|
| MS-31801 |
| pkh 26 |
| HY-D1451 |
| PD167419 |
| CS-0378565 |
Research
Studies (253)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 56 (22.13) | 18.2507 |
| 2000's | 94 (37.15) | 29.6817 |
| 2010's | 85 (33.60) | 24.3611 |
| 2020's | 18 (7.11) | 2.80 |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|
| Trials | 1 (0.39%) | 5.53% |
| Reviews | 3 (1.16%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 255 (98.46%) | 84.16% |
| Substance | Studies | Classes | Roles | First Year | Last Year | Average Age | Relationship Strength | Trials | pre-1990 | 1990's | 2000's | 2010's | post-2020 |
|---|
| adenine | | 6-aminopurines;
purine nucleobase | Daphnia magna metabolite;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| lactic acid | | 2-hydroxy monocarboxylic acid | algal metabolite;
Daphnia magna metabolite | 2007 | 2007 | 17.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| palmitic acid | | long-chain fatty acid;
straight-chain saturated fatty acid | algal metabolite;
Daphnia magna metabolite;
EC 1.1.1.189 (prostaglandin-E2 9-reductase) inhibitor;
plant metabolite | 2005 | 2005 | 19.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| antipyrine | | pyrazolone | antipyretic;
cyclooxygenase 3 inhibitor;
environmental contaminant;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
xenobiotic | 2015 | 2015 | 9.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| busulfan | | methanesulfonate ester | alkylating agent;
antineoplastic agent;
carcinogenic agent;
insect sterilant;
teratogenic agent | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| dapi | | indoles | fluorochrome | 2009 | 2009 | 15.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| erythrosine | | | | 1995 | 2022 | 19.5 | medium | 0 | 0 | 7 | 7 | 2 | 1 |
| fluorouracil | | nucleobase analogue;
organofluorine compound | antimetabolite;
antineoplastic agent;
environmental contaminant;
immunosuppressive agent;
radiosensitizing agent;
xenobiotic | 2021 | 2021 | 3.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| edaravone | | pyrazolone | antioxidant;
radical scavenger | 2015 | 2015 | 9.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| oxidopamine | | benzenetriol;
catecholamine;
primary amino compound | drug metabolite;
human metabolite;
neurotoxin | 2004 | 2007 | 18.5 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| ag 1879 | | aromatic amine;
monochlorobenzenes;
pyrazolopyrimidine | beta-adrenergic antagonist;
EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor;
geroprotector | 2007 | 2007 | 17.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| propidium | | phenanthridines;
quaternary ammonium ion | fluorochrome;
intercalator | 2002 | 2009 | 19.3 | low | 0 | 0 | 0 | 3 | 0 | 0 |
| prednisone | | 11-oxo steroid;
17alpha-hydroxy steroid;
20-oxo steroid;
21-hydroxy steroid;
3-oxo-Delta(1),Delta(4)-steroid;
C21-steroid;
glucocorticoid;
primary alpha-hydroxy ketone;
tertiary alpha-hydroxy ketone | adrenergic agent;
anti-inflammatory drug;
antineoplastic agent;
immunosuppressive agent;
prodrug | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| carbon tetrachloride | | chlorocarbon;
chloromethanes | hepatotoxic agent;
refrigerant | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| chlordan | | cyclodiene organochlorine insecticide | GABA-gated chloride channel antagonist;
persistent organic pollutant | 2000 | 2000 | 24.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| adenosine diphosphate | | adenosine 5'-phosphate;
purine ribonucleoside 5'-diphosphate | fundamental metabolite;
human metabolite | 2002 | 2002 | 22.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| bromodeoxyuridine | | pyrimidine 2'-deoxyribonucleoside | antimetabolite;
antineoplastic agent | 2002 | 2014 | 16.2 | low | 0 | 0 | 0 | 5 | 1 | 0 |
| cytarabine | | beta-D-arabinoside;
monosaccharide derivative;
pyrimidine nucleoside | antimetabolite;
antineoplastic agent;
antiviral agent;
immunosuppressive agent | 2002 | 2002 | 22.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| xanthenes | | xanthene | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| benzotriazole | | benzotriazoles | environmental contaminant;
xenobiotic | 2002 | 2002 | 22.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| cyanuric chloride | | chloro-1,3,5-triazine;
organochlorine compound | cross-linking reagent | 2002 | 2002 | 22.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| framycetin | | aminoglycoside | allergen;
antibacterial drug;
Escherichia coli metabolite | 1993 | 1993 | 31.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| azacitidine | | N-glycosyl-1,3,5-triazine;
nucleoside analogue | antineoplastic agent | 2015 | 2015 | 9.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| cuprizone | | organonitrogen compound;
organooxygen compound | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| gentian violet | | organic chloride salt | anthelminthic drug;
antibacterial agent;
antifungal agent;
antiseptic drug;
histological dye | 1994 | 1994 | 30.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| resazurin | | phenoxazine | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| acetylcysteine | | acetylcysteine;
L-cysteine derivative;
N-acetyl-L-amino acid | antidote to paracetamol poisoning;
antiinfective agent;
antioxidant;
antiviral drug;
ferroptosis inhibitor;
geroprotector;
human metabolite;
mucolytic;
radical scavenger;
vulnerary | 2021 | 2021 | 3.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| sodium hydroxide | | alkali metal hydroxide | | 2005 | 2005 | 19.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| zinc oxide | | zinc molecular entity | | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| vancomycin | | glycopeptide | antibacterial drug;
antimicrobial agent;
bacterial metabolite | 2007 | 2007 | 17.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| amiloride | | aromatic amine;
guanidines;
organochlorine compound;
pyrazines | diuretic;
sodium channel blocker | 2000 | 2000 | 24.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| fluorescein-5-isothiocyanate | | fluorescein isothiocyanate | | 1991 | 2015 | 24.2 | low | 0 | 0 | 3 | 0 | 1 | 0 |
| chromium | | chromium group element atom;
metal allergen | micronutrient | 2006 | 2006 | 18.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| tetradecanoylphorbol acetate | | acetate ester;
diester;
phorbol ester;
tertiary alpha-hydroxy ketone;
tetradecanoate ester | antineoplastic agent;
apoptosis inducer;
carcinogenic agent;
mitogen;
plant metabolite;
protein kinase C agonist;
reactive oxygen species generator | 1996 | 1998 | 27.0 | low | 0 | 0 | 2 | 0 | 0 | 0 |
| paclitaxel | | taxane diterpenoid;
tetracyclic diterpenoid | antineoplastic agent;
human metabolite;
metabolite;
microtubule-stabilising agent | 2009 | 2012 | 13.5 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| etoposide | | beta-D-glucoside;
furonaphthodioxole;
organic heterotetracyclic compound | antineoplastic agent;
DNA synthesis inhibitor | 2012 | 2012 | 12.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| colforsin | | acetate ester;
cyclic ketone;
labdane diterpenoid;
organic heterotricyclic compound;
tertiary alpha-hydroxy ketone;
triol | adenylate cyclase agonist;
anti-HIV agent;
antihypertensive agent;
plant metabolite;
platelet aggregation inhibitor;
protein kinase A agonist | 2002 | 2002 | 22.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| acridine orange | | aminoacridines;
aromatic amine;
tertiary amino compound | fluorochrome;
histological dye | 2009 | 2009 | 15.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| plerixafor | | azacycloalkane;
azamacrocycle;
benzenes;
crown amine;
secondary amino compound;
tertiary amino compound | anti-HIV agent;
antineoplastic agent;
C-X-C chemokine receptor type 4 antagonist;
immunological adjuvant | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| fluorexon | | xanthene dye | fluorochrome | 1999 | 2000 | 24.5 | low | 0 | 0 | 2 | 0 | 0 | 0 |
| triazoles | | 1,2,3-triazole | | 2002 | 2002 | 22.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| diacetyldichlorofluorescein | | | | 2022 | 2022 | 2.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| mosapride | | aromatic ether;
benzamides;
monochlorobenzenes;
monofluorobenzenes;
morpholines;
secondary carboxamide;
substituted aniline;
tertiary amino compound | | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| 5-chloromethylfluorescein diacetate | | acetate ester | fluorochrome | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| 5-((4,6-dichloro-1,3,5-triazin-2-yl)amino)fluorescein | | | | 1998 | 2000 | 25.0 | low | 0 | 0 | 2 | 0 | 0 | 0 |
| biotin | | biotins;
vitamin B7 | coenzyme;
cofactor;
Escherichia coli metabolite;
fundamental metabolite;
human metabolite;
mouse metabolite;
nutraceutical;
prosthetic group;
Saccharomyces cerevisiae metabolite | 2002 | 2002 | 22.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| wortmannin | | acetate ester;
cyclic ketone;
delta-lactone;
organic heteropentacyclic compound | anticoronaviral agent;
antineoplastic agent;
autophagy inhibitor;
EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor;
geroprotector;
Penicillium metabolite;
radiosensitizing agent | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| fibrin | | peptide | | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| bradykinin | | oligopeptide | human blood serum metabolite;
vasodilator agent | 2006 | 2006 | 18.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| elastin | | oligopeptide | | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| pectins | | D-galactopyranuronic acid | | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| decitabine | | 2'-deoxyribonucleoside | | 2015 | 2015 | 9.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| dactinomycin | | actinomycin | mutagen | 2009 | 2009 | 15.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| bromochloroacetic acid | | 2-bromocarboxylic acid;
monocarboxylic acid;
organochlorine compound | | 2001 | 2014 | 16.5 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| safranine t | | organic chloride salt | fluorochrome;
histological dye | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| ovalbumin | | | | 2012 | 2015 | 10.5 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| tetramethylrhodamine isothiocyanate | | | | 1995 | 1995 | 29.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| rhodamine 123 | | organic cation;
xanthene dye | fluorochrome | 2000 | 2000 | 24.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| myelin basic protein | | | | 2012 | 2012 | 12.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| alprostadil | | prostaglandins E | anticoagulant;
human metabolite;
platelet aggregation inhibitor;
vasodilator agent | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| sirolimus | | antibiotic antifungal drug;
cyclic acetal;
cyclic ketone;
ether;
macrolide lactam;
organic heterotricyclic compound;
secondary alcohol | antibacterial drug;
anticoronaviral agent;
antineoplastic agent;
bacterial metabolite;
geroprotector;
immunosuppressive agent;
mTOR inhibitor | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| clobetasol | | 11beta-hydroxy steroid;
17alpha-hydroxy steroid;
20-oxo steroid;
3-oxo-Delta(1),Delta(4)-steroid;
chlorinated steroid;
fluorinated steroid;
glucocorticoid;
tertiary alpha-hydroxy ketone | anti-inflammatory drug;
SMO receptor agonist | 1994 | 1994 | 30.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| 3,3'-dioctadecylindocarbocyanine | | Cy5 dye;
indolium ion | fluorochrome | 1995 | 1995 | 29.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| carbocyanines | | cyanine dye;
organic iodide salt | fluorochrome | 1995 | 2006 | 23.0 | low | 0 | 0 | 1 | 4 | 0 | 0 |
| involucrin | | | | 2014 | 2014 | 10.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| concanamycin a | | carbamate ester;
concanamycin | antifungal agent;
EC 3.6.3.14 (H(+)-transporting two-sector ATPase) inhibitor;
metabolite | 2003 | 2003 | 21.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| pkh 2 dye | | | | 2001 | 2001 | 23.0 | medium | 0 | 0 | 0 | 1 | 0 | 0 |
| fluorescein thiosemicarbazide | | | | 2000 | 2000 | 24.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| gadolinium dtpa | | gadolinium coordination entity | MRI contrast agent | 2010 | 2015 | 11.5 | low | 0 | 0 | 0 | 1 | 3 | 0 |
| sq-23377 | | cyclic ether;
enol;
polyunsaturated fatty acid;
very long-chain fatty acid | calcium ionophore;
metabolite | 1998 | 1998 | 26.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| 7-aminoactinomycin d | | | | 2009 | 2009 | 15.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| losartan potassium | | | | 1999 | 2019 | 11.8 | low | 0 | 0 | 1 | 0 | 3 | 0 |
| td-5108 | | | | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| technetium tc 99m exametazime | | | | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| acid phosphatase | | | | 2006 | 2006 | 18.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| ceruletide | | oligopeptide | diagnostic agent;
gastrointestinal drug | 2021 | 2021 | 3.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| hoe 33342 | | | | 1991 | 2014 | 23.0 | low | 0 | 0 | 3 | 0 | 1 | 0 |
| chitosan | | | | 2009 | 2023 | 8.0 | low | 0 | 0 | 0 | 1 | 0 | 1 |
| to-pro-3 | | cyanine dye;
organic iodide salt | fluorochrome | 2001 | 2001 | 23.0 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| ascorbic acid | | ascorbic acid;
vitamin C | coenzyme;
cofactor;
flour treatment agent;
food antioxidant;
food colour retention agent;
geroprotector;
plant metabolite;
skin lightening agent | 2021 | 2021 | 3.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| epidermal growth factor | | | | 2002 | 2002 | 22.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| transforming growth factor beta | | | | 2000 | 2000 | 24.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| cyclosporine | | | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| cytochalasin d | | | | 2014 | 2014 | 10.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| apyrase | | | | 2006 | 2006 | 18.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| trypan blue | | | | 1994 | 1994 | 30.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| concanavalin a | | | | 1998 | 1998 | 26.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| Condition | Indicated | Studies | First Year | Last Year | Average Age | Relationship Strength | Trials | pre-1990 | 1990's | 2000's | 2010's | post-2020 |
|---|
| Absence Status | 0 | | 2019 | 2019 | 5.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| ACL Injuries | 0 | | 2014 | 2014 | 10.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Acute Brain Injuries | 0 | | 2001 | 2014 | 15.3 | low | 0 | 0 | 0 | 1 | 2 | 0 |
| Acute Confusional Senile Dementia | 0 | | 2012 | 2015 | 10.3 | low | 0 | 0 | 0 | 0 | 3 | 0 |
| Acute Disease | 0 | | 1994 | 2002 | 25.0 | low | 0 | 0 | 1 | 2 | 0 | 0 |
| Acute Edematous Pancreatitis | 0 | | 2021 | 2021 | 3.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| Acute Hemolytic Transfusion Reaction | 0 | | 2001 | 2001 | 23.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Acute Hepatic Failure | 0 | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Acute Kidney Failure | 0 | | 2015 | 2015 | 9.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Acute Kidney Injury | 0 | | 2015 | 2015 | 9.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Acute Myelogenous Leukemia | 0 | | 1994 | 2000 | 27.0 | low | 0 | 0 | 2 | 0 | 0 | 0 |
| Adenocarcinoma | 0 | | 2004 | 2004 | 20.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Adenocarcinoma, Basal Cell | 0 | | 2004 | 2004 | 20.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Adhesions, Tissue | 0 | | 2018 | 2018 | 6.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| African Lymphoma | 0 | | 2000 | 2003 | 22.5 | low | 0 | 0 | 1 | 1 | 0 | 0 |
| Age-Related Memory Disorders | 0 | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Aging | 0 | | 2002 | 2002 | 22.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| AIDS, Simian | 0 | | 2006 | 2006 | 18.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Airway Hyper-Responsiveness | 0 | | 2015 | 2015 | 9.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Akinetic-Rigid Variant of Huntington Disease | 0 | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Alloxan Diabetes | 0 | | 2017 | 2017 | 7.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Alzheimer Disease | 0 | | 2012 | 2015 | 10.3 | low | 0 | 0 | 0 | 0 | 3 | 0 |
| Amyloid Angiopathy, Cerebral | 0 | | 2015 | 2015 | 9.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Aneuploid | 0 | | 1993 | 2009 | 23.0 | low | 0 | 0 | 1 | 1 | 0 | 0 |
| Angiogenesis, Pathologic | 0 | | 2022 | 2022 | 2.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| Anoxia-Ischemia, Brain | 0 | | 2014 | 2014 | 10.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Anterior Cerebral Circulation Infarction | 0 | | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Apoplexy | 0 | | 2009 | 2009 | 15.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Arthritis, Degenerative | 0 | | 2014 | 2014 | 10.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Arthropathies | 0 | | 2003 | 2014 | 15.5 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| Astrocytoma, Grade IV | 0 | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Atrophy | 0 | | 2004 | 2004 | 20.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Autoimmune Diabetes | 0 | | 1994 | 1994 | 30.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| Autoimmune Disease | 0 | | 1998 | 1998 | 26.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| Autoimmune Diseases | 0 | | 1998 | 1998 | 26.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| Autosomal Dominant Juvenile Parkinson Disease | 0 | | 2004 | 2007 | 18.5 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| B-Cell Leukemia | 0 | | 2000 | 2000 | 24.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| B-Cell Lymphoma | 0 | | 2003 | 2003 | 21.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| B16 Melanoma | 0 | | 1991 | 1991 | 33.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| Bare Lymphocyte Syndrome | 0 | | 1995 | 1995 | 29.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| Benign Neoplasms, Brain | 0 | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Blood Clot | 0 | | 1994 | 1994 | 30.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| Blunt Injuries | 0 | | 2018 | 2018 | 6.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Body Weight | 0 | | 2021 | 2021 | 3.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| Brain Infarction | 0 | | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Brain Injuries | 0 | | 2001 | 2014 | 15.3 | low | 0 | 0 | 0 | 1 | 2 | 0 |
| Brain Ischemia | 0 | | 2007 | 2007 | 17.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Brain Neoplasms | 0 | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Branch Vein Occlusion | 0 | | 2001 | 2001 | 23.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Breast Cancer | 0 | | 2013 | 2022 | 7.7 | low | 0 | 0 | 0 | 0 | 2 | 1 |
| Breast Neoplasms | 0 | | 2013 | 2022 | 7.7 | low | 0 | 0 | 0 | 0 | 2 | 1 |
| Burkitt Lymphoma | 0 | | 2000 | 2003 | 22.5 | low | 0 | 0 | 1 | 1 | 0 | 0 |
| Burns | 0 | | 2019 | 2019 | 5.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Cancer of Cervix | 0 | | 2022 | 2022 | 2.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| Cancer of Liver | 0 | | 1991 | 2016 | 20.5 | low | 0 | 0 | 1 | 0 | 1 | 0 |
| Cancer of Lung | 0 | | 1991 | 1993 | 32.0 | low | 0 | 0 | 2 | 0 | 0 | 0 |
| Cancer of Nasopharynx | 0 | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Cancer of Ovary | 0 | | 2009 | 2012 | 13.5 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| Cancer of Prostate | 0 | | 2004 | 2004 | 20.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Cancer of Stomach | 0 | | 2012 | 2021 | 7.5 | low | 0 | 0 | 0 | 0 | 1 | 1 |
| Canine Diseases | 0 | | 2014 | 2014 | 10.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Carcinoma | 0 | | 2012 | 2013 | 11.5 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| Carcinoma, Anaplastic | 0 | | 2012 | 2013 | 11.5 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| Carcinoma, Hepatocellular | 0 | | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Cardiac Diseases | 0 | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Cardiac Rupture, Traumatic | 0 | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Cardiovascular Stroke | 0 | | 2009 | 2023 | 10.2 | low | 0 | 0 | 0 | 2 | 1 | 1 |
| Carotid Artery Narrowing | 0 | | 2001 | 2001 | 23.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Carotid Stenosis | 0 | | 2001 | 2001 | 23.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Cartilage Diseases | 0 | | 2006 | 2006 | 18.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Cell Transformation, Neoplastic | 0 | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Cerebral Amyloid Angiopathy | 0 | | 2015 | 2015 | 9.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Cerebral Infarction, Middle Cerebral Artery | 0 | | 2009 | 2009 | 15.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Cerebral Ischemia | 0 | | 2007 | 2007 | 17.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Chest Injuries | 0 | | 2018 | 2018 | 6.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Chondromalacia | 0 | | 2006 | 2006 | 18.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Chronic Kidney Diseases | 0 | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Chronic Lung Injury | 0 | | 2015 | 2015 | 9.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Cirrhosis, Liver | 0 | | 2008 | 2014 | 13.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| CJD (Creutzfeldt-Jakob Disease) | 0 | | 2001 | 2001 | 23.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Clinically Isolated CNS Demyelinating Syndrome | 0 | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Co-infection | 0 | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Complication, Postoperative | 0 | | 2006 | 2006 | 18.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Constriction, Pathologic | 0 | | 2022 | 2022 | 2.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| Constriction, Pathological | 0 | | 2022 | 2022 | 2.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| Creutzfeldt-Jakob Syndrome | 0 | | 2001 | 2001 | 23.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Cystadenocarcinoma, Serous | 0 | | 2009 | 2009 | 15.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Deep Vein Thrombosis | 0 | | 2001 | 2001 | 23.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Degenerative Disc Disease | 0 | | 2015 | 2015 | 9.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Delayed Hypersensitivity | 0 | | 1994 | 1994 | 30.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| Demyelinating Diseases | 0 | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Diabetes Mellitus | 0 | | 2022 | 2022 | 2.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| Diabetes Mellitus, Type 1 | 0 | | 1994 | 1994 | 30.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| Disc, Herniated | 0 | | 2003 | 2003 | 21.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Disease Models, Animal | 0 | | 1998 | 2019 | 14.3 | low | 0 | 0 | 2 | 8 | 10 | 0 |
| EHS Tumor | 0 | | 1991 | 1991 | 33.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| Experimental Hepatoma | 0 | | 2000 | 2000 | 24.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| Experimental Neoplasms | 0 | | 1993 | 2011 | 22.0 | low | 0 | 0 | 1 | 0 | 1 | 0 |
| Extravascular Hemolysis | 0 | | 2014 | 2014 | 10.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Fat Necrosis | 0 | | 2006 | 2006 | 18.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Fatty Liver, Nonalcoholic | 0 | | 2021 | 2021 | 3.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| Fibrosarcoma | 0 | | 2000 | 2000 | 24.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| Glaucoma, Suspect | 0 | | 1995 | 1995 | 29.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| Glioblastoma | 0 | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Graft Occlusion, Vascular | 0 | | 1994 | 1994 | 30.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| Granulocytic Leukemia | 0 | | 2002 | 2002 | 22.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Haemonchiasis | 0 | | 2000 | 2000 | 24.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| Hansen Disease | 0 | | 2005 | 2005 | 19.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Hay Fever | 0 | | 2003 | 2003 | 21.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Heart Disease, Ischemic | 0 | | 2007 | 2007 | 17.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Heart Diseases | 0 | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Hemolysis | 0 | | 2014 | 2014 | 10.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Hepatocellular Carcinoma | 0 | | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| HIV | 0 | | 2012 | 2012 | 12.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| HIV Coinfection | 0 | | 1994 | 2006 | 24.0 | low | 0 | 0 | 1 | 1 | 0 | 0 |
| HIV Infections | 0 | | 1994 | 2006 | 24.0 | low | 0 | 0 | 1 | 1 | 0 | 0 |
| Huntington Disease | 0 | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Hyperlipemia | 0 | | 2021 | 2021 | 3.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| Hyperlipidemias | 0 | | 2021 | 2021 | 3.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| Hyperoxia | 0 | | 2015 | 2015 | 9.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Hypoxia-Ischemia, Brain | 0 | | 2014 | 2014 | 10.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Infarction, Middle Cerebral Artery | 0 | | 2009 | 2009 | 15.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Infections, Orthomyxoviridae | 0 | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Infections, Pneumococcal | 0 | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Infections, Tick-Borne | 0 | | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Inflammation | 0 | | 2007 | 2023 | 9.2 | low | 0 | 0 | 0 | 1 | 2 | 1 |
| Injuries | 0 | | 2017 | 2017 | 7.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Injuries, Radiation | 0 | | 2001 | 2001 | 23.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Injuries, Soft Tissue | 0 | | 2006 | 2006 | 18.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Injuries, Spinal Cord | 0 | | 2015 | 2017 | 8.0 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| Injury, Ischemia-Reperfusion | 0 | | 2015 | 2015 | 9.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Innate Inflammatory Response | 0 | | 2007 | 2023 | 9.2 | low | 0 | 0 | 0 | 1 | 2 | 1 |
| Intervertebral Disc Degeneration | 0 | | 2015 | 2015 | 9.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Intervertebral Disc Displacement | 0 | | 2003 | 2003 | 21.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Intraocular Pressure | 0 | | 1995 | 1995 | 29.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| Ischemia | 0 | | 2014 | 2022 | 7.3 | low | 0 | 0 | 0 | 0 | 2 | 1 |
| Joint Diseases | 0 | | 2003 | 2014 | 15.5 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| Koch's Disease | 0 | | 2012 | 2012 | 12.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Left Ventricular Dysfunction | 0 | | 2009 | 2009 | 15.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Leprosy | 0 | | 2005 | 2005 | 19.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Leucocythaemia | 0 | | 1993 | 2011 | 22.0 | low | 0 | 0 | 1 | 0 | 1 | 0 |
| Leukemia | 0 | | 1993 | 2011 | 22.0 | low | 0 | 0 | 1 | 0 | 1 | 0 |
| Leukemia, Lymphocytic, T Cell | 0 | | 2000 | 2000 | 24.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| Leukemia, Myeloid | 0 | | 2002 | 2002 | 22.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Leukemia, Myeloid, Acute | 0 | | 1994 | 2000 | 27.0 | low | 0 | 0 | 2 | 0 | 0 | 0 |
| Leukemia, Pre-B-Cell | 0 | | 1994 | 1994 | 30.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| Leukemia, T-Cell | 0 | | 2000 | 2000 | 24.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| Liver Cirrhosis | 0 | | 2008 | 2014 | 13.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| Liver Failure, Acute | 0 | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Liver Neoplasms | 0 | | 1991 | 2016 | 20.5 | low | 0 | 0 | 1 | 0 | 1 | 0 |
| Lung Neoplasms | 0 | | 1991 | 1993 | 32.0 | low | 0 | 0 | 2 | 0 | 0 | 0 |
| Lymph Node Metastasis | 0 | | 2000 | 2000 | 24.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| Lymphoma, B-Cell | 0 | | 2003 | 2003 | 21.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Memory Disorders | 0 | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Meniscitis | 0 | | 2005 | 2005 | 19.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Microbial Superinvasion | 0 | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Muscle Contraction | 0 | | 2017 | 2017 | 7.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Myocardial Infarction | 0 | | 2009 | 2023 | 10.2 | low | 0 | 0 | 0 | 2 | 1 | 1 |
| Myocardial Ischemia | 0 | | 2007 | 2007 | 17.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Nasopharyngeal Carcinoma | 0 | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Nasopharyngeal Neoplasms | 0 | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Necrosis | 0 | | 2003 | 2014 | 14.7 | low | 0 | 0 | 0 | 1 | 2 | 0 |
| Neuroretinitis | 0 | | 1998 | 1998 | 26.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| Non-alcoholic Fatty Liver Disease | 0 | | 2021 | 2021 | 3.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| Obesity | 0 | | 2007 | 2007 | 17.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Ocular Hypertension | 0 | | 1995 | 1995 | 29.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| Orthomyxoviridae Infections | 0 | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Osteoarthritis | 0 | | 2014 | 2014 | 10.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Osteogenic Sarcoma | 0 | | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Osteomyelitis | 0 | | 2007 | 2007 | 17.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Osteosarcoma | 0 | | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Ovarian Neoplasms | 0 | | 2009 | 2012 | 13.5 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| Pancreatitis | 0 | | 2021 | 2021 | 3.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| Parkinsonian Disorders | 0 | | 2004 | 2007 | 18.5 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| Pelvic Organ Prolapse | 0 | | 2017 | 2017 | 7.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Peripheral Nerve Injuries | 0 | | 2011 | 2017 | 10.0 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| Peripheral Nerve Injury | 0 | | 2011 | 2017 | 10.0 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| Peritoneal Carcinomatosis | 0 | | 2000 | 2000 | 24.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| Peritoneal Neoplasms | 0 | | 2000 | 2000 | 24.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| Pheochromocytoma | 0 | | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Pheochromocytoma, Extra-Adrenal | 0 | | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Pneumococcal Infections | 0 | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Postoperative Complications | 0 | | 2006 | 2006 | 18.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 0 | | 1994 | 1994 | 30.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| Pregnancy | 0 | | 1998 | 2014 | 18.0 | low | 0 | 0 | 1 | 1 | 1 | 0 |
| Prostatic Neoplasms | 0 | | 2004 | 2004 | 20.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Renal Insufficiency, Chronic | 0 | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Reperfusion Injury | 0 | | 2015 | 2015 | 9.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Retinal Vein Occlusion | 0 | | 2001 | 2001 | 23.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Retinitis | 0 | | 1998 | 1998 | 26.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| Rhinitis, Allergic, Seasonal | 0 | | 2003 | 2003 | 21.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Rupture | 0 | | 2014 | 2014 | 10.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Sensitivity and Specificity | 0 | | 1997 | 2009 | 21.0 | low | 0 | 0 | 1 | 4 | 0 | 0 |
| Severe Combined Immunodeficiency | 0 | | 1995 | 1995 | 29.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| Spinal Cord Injuries | 0 | | 2015 | 2017 | 8.0 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| Status Epilepticus | 0 | | 2019 | 2019 | 5.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Stomach Neoplasms | 0 | | 2012 | 2021 | 7.5 | low | 0 | 0 | 0 | 0 | 1 | 1 |
| Stroke | 0 | | 2009 | 2009 | 15.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Thrombosis | 0 | | 1994 | 1994 | 30.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| Toxoplasmosis, Animal | 0 | | 1998 | 1998 | 26.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| Transfusion Reaction | 0 | | 2001 | 2001 | 23.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Tuberculosis | 0 | | 2012 | 2012 | 12.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Urogenital Prolapse | 0 | | 2017 | 2017 | 7.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Uterine Cervical Neoplasms | 0 | | 2022 | 2022 | 2.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| Uveitis, Anterior | 0 | | 1998 | 1998 | 26.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| Uveitis, Posterior | 0 | | 1998 | 1998 | 26.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| Venous Thrombosis | 0 | | 2001 | 2001 | 23.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Ventricular Dysfunction, Left | 0 | | 2009 | 2009 | 15.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Weight Gain | 0 | | 2015 | 2015 | 9.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Wounds and Injuries | 0 | | 2017 | 2017 | 7.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
Stromal cells prevent apoptosis of AML cells by up-regulation of anti-apoptotic proteins.Leukemia, , Volume: 16, Issue:9, 2002
Capillary blood flow in acute branch retinal vein occlusion.Retina (Philadelphia, Pa.), , Volume: 21, Issue:5, 2001
Measurement of the growth parameters of precursor B-acute lymphoblastic leukaemic cells in co-culture with bone marrow stromal cells; detection of two cd10 positive populations with different proliferative capacities and survival.Leukemia research, , Volume: 18, Issue:1, 1994
Platelets in the Alzheimer's disease brain: do they play a role in cerebral amyloid angiopathy?Current neurovascular research, , Volume: 12, Issue:1, 2015
The hematopoietic growth factor "erythropoietin" enhances the therapeutic effect of mesenchymal stem cells in Alzheimer's disease.Pakistan journal of biological sciences : PJBS, , Jan-01, Volume: 17, Issue:1, 2014
[Migration of PKH26-labeled mesenchymal stem cells in rats with Alzheimer's disease].Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences, , Volume: 41, Issue:6, 2012
Intranasally administered mesenchymal stem cells promote a regenerative niche for repair of neonatal ischemic brain injury.Experimental neurology, , Volume: 261, 2014
Early distribution of intravenously injected mesenchymal stem cells in rats with acute brain trauma evaluated by (99m)Tc-HMPAO labeling.Nuclear medicine and biology, , Volume: 38, Issue:8, 2011
Preservation of neurotrophin expression in microglia that migrate into the gerbil's brain across the blood-brain barrier.Neuroscience letters, , Oct-19, Volume: 312, Issue:2, 2001
Confocal microscopy analysis reveals that only a small proportion of extracellular vesicles are successfully labelled with commonly utilised staining methods.Scientific reports, , 01-07, Volume: 12, Issue:1, 2022
Regulation of exosome release from mammary epithelial and breast cancer cells - a new regulatory pathway.European journal of cancer (Oxford, England : 1990), , Volume: 50, Issue:5, 2014
Breast cancer-derived microparticles display tissue selectivity in the transfer of resistance proteins to cells.PloS one, , Volume: 8, Issue:4, 2013
Spontaneous membrane transfer through homotypic synapses between lymphoma cells.Journal of immunology (Baltimore, Md. : 1950), , Sep-01, Volume: 171, Issue:5, 2003
Intercellular adhesion can be visualized using fluorescently labeled fibrosarcoma HT1080 cells cocultured with hematopoietic cell lines or CD34(+) enriched human mobilized peripheral blood cells.Cytometry, , Jun-01, Volume: 40, Issue:2, 2000
MYC regulation of CHK1 and CHK2 promotes radioresistance in a stem cell-like population of nasopharyngeal carcinoma cells.Cancer research, , Feb-01, Volume: 73, Issue:3, 2013
Ovarian carcinoma tumor-initiating cells have a mesenchymal phenotype.Cell cycle (Georgetown, Tex.), , May-15, Volume: 11, Issue:10, 2012
Novel method to assess resident alveolar macrophage efferocytosis of apoptotic neutrophils by flow cytometry.Toxicology and applied pharmacology, , Feb-01, Volume: 460, 2023
Reduced immune responses in chimeric mice engrafted with bone marrow cells from mice with airways inflammation.Inflammation research : official journal of the European Histamine Research Society ... [et al.], , Volume: 64, Issue:11, 2015
Protective effects of Gingko biloba extract 761 on myocardial infarction via improving the viability of implanted mesenchymal stem cells in the rat heart.Molecular medicine reports, , Volume: 9, Issue:4, 2014
Increased inflammatory properties of adipose tissue macrophages recruited during diet-induced obesity.Diabetes, , Volume: 56, Issue:1, 2007
Involvement of endothelial progenitor cells in blood flow recovery through activation of the Wnt/β-catenin signaling pathway and inhibition of high oxidative stress in diabetic hindlimb ischemic rats.Advances in clinical and experimental medicine : official organ Wroclaw Medical University, , Volume: 31, Issue:11, 2022
Optimal administration routes for adipose-derived stem cells therapy in ischaemic flaps.Journal of tissue engineering and regenerative medicine, , Volume: 8, Issue:8, 2014
Intranasally administered mesenchymal stem cells promote a regenerative niche for repair of neonatal ischemic brain injury.Experimental neurology, , Volume: 261, 2014
Activation of human T-helper/inducer cell, T-cytotoxic cell, B-cell, and natural killer (NK)-cells and induction of natural killer cell activity against K562 chronic myeloid leukemia cells with modified citrus pectin.BMC complementary and alternative medicine, , Aug-04, Volume: 11, 2011
A novel approach to the measurement of different in vitro leukaemic cell growth parameters: the use of PKH GL fluorescent probes.Leukemia research, , Volume: 17, Issue:10, 1993
[Treatment of liver cancer in vitro and in mice by monoclonal antibody targeting epithelial specific antigen-positive liver cancer stem cells in combination with cisplatin].Zhonghua zhong liu za zhi [Chinese journal of oncology], , May-23, Volume: 38, Issue:5, 2016
Accumulation of adoptively transferred adherent, lymphokine-activated killer cells in murine metastases.The Journal of experimental medicine, , Aug-01, Volume: 174, Issue:2, 1991
Mechanisms of adoptive immunotherapy: improved methods for in vivo tracking of tumor-infiltrating lymphocytes and lymphokine-activated killer cells.Cancer research, , May-15, Volume: 53, Issue:10 Suppl, 1993
Accumulation of adoptively transferred adherent, lymphokine-activated killer cells in murine metastases.The Journal of experimental medicine, , Aug-01, Volume: 174, Issue:2, 1991
Promoting early neovascularization by allotransplanted adipose-derived Muse cells in an ovine model of acute myocardial infarction.PloS one, , Volume: 18, Issue:1, 2023
Protective effects of Gingko biloba extract 761 on myocardial infarction via improving the viability of implanted mesenchymal stem cells in the rat heart.Molecular medicine reports, , Volume: 9, Issue:4, 2014
Functional improvement of infarcted heart by co-injection of embryonic stem cells with temperature-responsive chitosan hydrogel.Tissue engineering. Part A, , Volume: 15, Issue:6, 2009
Cell tracking and therapy evaluation of bone marrow monocytes and stromal cells using SPECT and CMR in a canine model of myocardial infarction.Journal of cardiovascular magnetic resonance : official journal of the Society for Cardiovascular Magnetic Resonance, , Apr-27, Volume: 11, 2009
Optimal administration routes for adipose-derived stem cells therapy in ischaemic flaps.Journal of tissue engineering and regenerative medicine, , Volume: 8, Issue:8, 2014
Early distribution of intravenously injected mesenchymal stem cells in rats with acute brain trauma evaluated by (99m)Tc-HMPAO labeling.Nuclear medicine and biology, , Volume: 38, Issue:8, 2011
Measurement in vivo of the survival rate in autologous adipocyte transplantation.Plastic and reconstructive surgery, , Volume: 111, Issue:7, 2003
Ovarian carcinoma tumor-initiating cells have a mesenchymal phenotype.Cell cycle (Georgetown, Tex.), , May-15, Volume: 11, Issue:10, 2012
Cancer stem cells and aneuploid populations within developing tumors are the major determinants of tumor dormancy.Cancer research, , Dec-15, Volume: 69, Issue:24, 2009
[Effect of bone marrow cells transplantation on the decidua formation in pseudopregnant rats].Tsitologiia, , Volume: 56, Issue:4, 2014
Colostrum induced phenotypic and trafficking changes in maternal mononuclear cells in a peripheral blood leukocyte model for study of leukocyte transfer to the neonatal calf.Veterinary immunology and immunopathology, , Jan-15, Volume: 109, Issue:1-2, 2006
Alloantigen-induced unresponsiveness in cord blood T lymphocytes is associated with defective activation of Ras.Proceedings of the National Academy of Sciences of the United States of America, , Apr-14, Volume: 95, Issue:8, 1998
A new flow cytometric assay for the simultaneous analysis of antigen-specific elimination of T cells in heterogeneous T cell populations.Journal of immunological methods, , May-31, Volume: 344, Issue:2, 2009
Quantitative comparison of the sensitivity of detection of fluorescent and bioluminescent reporters in animal models.Molecular imaging, , Volume: 3, Issue:1, 2004
The flow cytometric PKH-26 assay for the determination of T-cell mediated cytotoxic activity.Methods (San Diego, Calif.), , Volume: 31, Issue:2, 2003
An improved flow cytometric assay for the determination of cytotoxic T lymphocyte activity.Journal of immunological methods, , Jan-01, Volume: 259, Issue:1-2, 2002
Molecular mechanisms of erythrophagocytosis: flow cytometric quantitation of in vitro erythrocyte phagocytosis by macrophages.Cytometry, , Oct-15, Volume: 30, Issue:5, 1997
Intercellular adhesion can be visualized using fluorescently labeled fibrosarcoma HT1080 cells cocultured with hematopoietic cell lines or CD34(+) enriched human mobilized peripheral blood cells.Cytometry, , Jun-01, Volume: 40, Issue:2, 2000
Flow cytometric analysis of natural killer cell function as a clinical assay.Cytometry, , May-01, Volume: 16, Issue:1, 1994
A simplified method for the rapid fluorometric assessment of antibody-dependent cell-mediated cytotoxicity.Journal of immunological methods, , Jan-20, Volume: 308, Issue:1-2, 2006
Flow cytometric analysis of natural killer cell function as a clinical assay.Cytometry, , May-01, Volume: 16, Issue:1, 1994
Platelets in the Alzheimer's disease brain: do they play a role in cerebral amyloid angiopathy?Current neurovascular research, , Volume: 12, Issue:1, 2015
The hematopoietic growth factor "erythropoietin" enhances the therapeutic effect of mesenchymal stem cells in Alzheimer's disease.Pakistan journal of biological sciences : PJBS, , Jan-01, Volume: 17, Issue:1, 2014
[Migration of PKH26-labeled mesenchymal stem cells in rats with Alzheimer's disease].Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences, , Volume: 41, Issue:6, 2012
Intranasally administered mesenchymal stem cells promote a regenerative niche for repair of neonatal ischemic brain injury.Experimental neurology, , Volume: 261, 2014
Early distribution of intravenously injected mesenchymal stem cells in rats with acute brain trauma evaluated by (99m)Tc-HMPAO labeling.Nuclear medicine and biology, , Volume: 38, Issue:8, 2011
Preservation of neurotrophin expression in microglia that migrate into the gerbil's brain across the blood-brain barrier.Neuroscience letters, , Oct-19, Volume: 312, Issue:2, 2001
Confocal microscopy analysis reveals that only a small proportion of extracellular vesicles are successfully labelled with commonly utilised staining methods.Scientific reports, , 01-07, Volume: 12, Issue:1, 2022
Regulation of exosome release from mammary epithelial and breast cancer cells - a new regulatory pathway.European journal of cancer (Oxford, England : 1990), , Volume: 50, Issue:5, 2014
Breast cancer-derived microparticles display tissue selectivity in the transfer of resistance proteins to cells.PloS one, , Volume: 8, Issue:4, 2013
Spontaneous membrane transfer through homotypic synapses between lymphoma cells.Journal of immunology (Baltimore, Md. : 1950), , Sep-01, Volume: 171, Issue:5, 2003
Intercellular adhesion can be visualized using fluorescently labeled fibrosarcoma HT1080 cells cocultured with hematopoietic cell lines or CD34(+) enriched human mobilized peripheral blood cells.Cytometry, , Jun-01, Volume: 40, Issue:2, 2000
MYC regulation of CHK1 and CHK2 promotes radioresistance in a stem cell-like population of nasopharyngeal carcinoma cells.Cancer research, , Feb-01, Volume: 73, Issue:3, 2013
Ovarian carcinoma tumor-initiating cells have a mesenchymal phenotype.Cell cycle (Georgetown, Tex.), , May-15, Volume: 11, Issue:10, 2012
Intranasally Administered Human MSC-Derived Extracellular Vesicles Pervasively Incorporate into Neurons and Microglia in both Intact and Status Epilepticus Injured Forebrain.International journal of molecular sciences, , Dec-26, Volume: 21, Issue:1, 2019
Systemic recovery and therapeutic effects of transplanted allogenic and xenogenic mesenchymal stromal cells in a rat blunt chest trauma model.Cytotherapy, , Volume: 20, Issue:2, 2018
EPO-releasing neural precursor cells promote axonal regeneration and recovery of function in spinal cord traumatic injury.Restorative neurology and neuroscience, , Volume: 35, Issue:6, 2017
Fetal Kidney Cells Can Ameliorate Ischemic Acute Renal Failure in Rats through Their Anti-Inflammatory, Anti-Apoptotic and Anti-Oxidative Effects.PloS one, , Volume: 10, Issue:6, 2015
Reduced immune responses in chimeric mice engrafted with bone marrow cells from mice with airways inflammation.Inflammation research : official journal of the European Histamine Research Society ... [et al.], , Volume: 64, Issue:11, 2015
Platelets in the Alzheimer's disease brain: do they play a role in cerebral amyloid angiopathy?Current neurovascular research, , Volume: 12, Issue:1, 2015
Protective effects of Gingko biloba extract 761 on myocardial infarction via improving the viability of implanted mesenchymal stem cells in the rat heart.Molecular medicine reports, , Volume: 9, Issue:4, 2014
Cartilage regeneration by chondrogenic induced adult stem cells in osteoarthritic sheep model.PloS one, , Volume: 9, Issue:6, 2014
Osteogenesis of heterotopically transplanted mesenchymal stromal cells in rat models of chronic kidney disease.Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, , Volume: 28, Issue:12, 2013
[Migration of PKH26-labeled mesenchymal stem cells in rats with Alzheimer's disease].Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences, , Volume: 41, Issue:6, 2012
Granulocyte colony-stimulating factor enhances bone marrow mononuclear cell homing to the liver in a mouse model of acute hepatic injury.Digestive diseases and sciences, , Volume: 55, Issue:10, 2010
Stem cell factor and mesenchymal and neural stem cell transplantation in a rat model of Huntington's disease.Molecular and cellular neurosciences, , Volume: 37, Issue:3, 2008
Development of a biodegradable alginate carrier system for antibiotics and bone cells.Journal of orthopaedic research : official publication of the Orthopaedic Research Society, , Volume: 25, Issue:1, 2007
Transplantation of immortalized mesencephalic progenitors (CSM14.1 cells) into the neonatal parkinsonian rat caudate putamen.Journal of neuroscience research, , Volume: 85, Issue:4, 2007
Effects of purification and fluorescent staining on viability of Mycobacterium leprae.International journal of leprosy and other mycobacterial diseases : official organ of the International Leprosy Association, , Volume: 73, Issue:3, 2005
Expanded phenotypically stable chondrocytes persist in the repair tissue and contribute to cartilage matrix formation and structural integration in a goat model of autologous chondrocyte implantation.Journal of orthopaedic research : official publication of the Orthopaedic Research Society, , Volume: 21, Issue:1, 2003
An experimental study of the regeneration of the intervertebral disc with an allograft of cultured annulus fibrosus cells using a tissue-engineering method.Spine, , Mar-15, Volume: 28, Issue:6, 2003
Recruitment of labelled monocytes by experimental venous thrombi.Thrombosis and haemostasis, , Volume: 85, Issue:6, 2001
Experimental study of lymphogenous peritoneal cancer dissemination: migration of fluorescent-labelled tumor cells in a rat model of mesenteric lymph vessel obstruction.Journal of experimental & clinical cancer research : CR, , Volume: 19, Issue:2, 2000
T cell traffic and the inflammatory response in experimental autoimmune uveoretinitis.Investigative ophthalmology & visual science, , Volume: 39, Issue:5, 1998
Novel method to assess resident alveolar macrophage efferocytosis of apoptotic neutrophils by flow cytometry.Toxicology and applied pharmacology, , Feb-01, Volume: 460, 2023
Reduced immune responses in chimeric mice engrafted with bone marrow cells from mice with airways inflammation.Inflammation research : official journal of the European Histamine Research Society ... [et al.], , Volume: 64, Issue:11, 2015
Protective effects of Gingko biloba extract 761 on myocardial infarction via improving the viability of implanted mesenchymal stem cells in the rat heart.Molecular medicine reports, , Volume: 9, Issue:4, 2014
Increased inflammatory properties of adipose tissue macrophages recruited during diet-induced obesity.Diabetes, , Volume: 56, Issue:1, 2007
Activation of human T-helper/inducer cell, T-cytotoxic cell, B-cell, and natural killer (NK)-cells and induction of natural killer cell activity against K562 chronic myeloid leukemia cells with modified citrus pectin.BMC complementary and alternative medicine, , Aug-04, Volume: 11, 2011
A novel approach to the measurement of different in vitro leukaemic cell growth parameters: the use of PKH GL fluorescent probes.Leukemia research, , Volume: 17, Issue:10, 1993
[Treatment of liver cancer in vitro and in mice by monoclonal antibody targeting epithelial specific antigen-positive liver cancer stem cells in combination with cisplatin].Zhonghua zhong liu za zhi [Chinese journal of oncology], , May-23, Volume: 38, Issue:5, 2016
Accumulation of adoptively transferred adherent, lymphokine-activated killer cells in murine metastases.The Journal of experimental medicine, , Aug-01, Volume: 174, Issue:2, 1991
Mechanisms of adoptive immunotherapy: improved methods for in vivo tracking of tumor-infiltrating lymphocytes and lymphokine-activated killer cells.Cancer research, , May-15, Volume: 53, Issue:10 Suppl, 1993
Accumulation of adoptively transferred adherent, lymphokine-activated killer cells in murine metastases.The Journal of experimental medicine, , Aug-01, Volume: 174, Issue:2, 1991
Promoting early neovascularization by allotransplanted adipose-derived Muse cells in an ovine model of acute myocardial infarction.PloS one, , Volume: 18, Issue:1, 2023
Protective effects of Gingko biloba extract 761 on myocardial infarction via improving the viability of implanted mesenchymal stem cells in the rat heart.Molecular medicine reports, , Volume: 9, Issue:4, 2014
Cell tracking and therapy evaluation of bone marrow monocytes and stromal cells using SPECT and CMR in a canine model of myocardial infarction.Journal of cardiovascular magnetic resonance : official journal of the Society for Cardiovascular Magnetic Resonance, , Apr-27, Volume: 11, 2009
Functional improvement of infarcted heart by co-injection of embryonic stem cells with temperature-responsive chitosan hydrogel.Tissue engineering. Part A, , Volume: 15, Issue:6, 2009
Identification and gene expression profiling of tumor-initiating cells isolated from human osteosarcoma cell lines in an orthotopic mouse model.Cancer biology & therapy, , Aug-15, Volume: 12, Issue:4, 2011
Mechanisms of adoptive immunotherapy: improved methods for in vivo tracking of tumor-infiltrating lymphocytes and lymphokine-activated killer cells.Cancer research, , May-15, Volume: 53, Issue:10 Suppl, 1993
Ovarian carcinoma tumor-initiating cells have a mesenchymal phenotype.Cell cycle (Georgetown, Tex.), , May-15, Volume: 11, Issue:10, 2012
Cancer stem cells and aneuploid populations within developing tumors are the major determinants of tumor dormancy.Cancer research, , Dec-15, Volume: 69, Issue:24, 2009
Intercellular adhesion can be visualized using fluorescently labeled fibrosarcoma HT1080 cells cocultured with hematopoietic cell lines or CD34(+) enriched human mobilized peripheral blood cells.Cytometry, , Jun-01, Volume: 40, Issue:2, 2000
Flow cytometric analysis of natural killer cell function as a clinical assay.Cytometry, , May-01, Volume: 16, Issue:1, 1994
A simplified method for the rapid fluorometric assessment of antibody-dependent cell-mediated cytotoxicity.Journal of immunological methods, , Jan-20, Volume: 308, Issue:1-2, 2006
Flow cytometric analysis of natural killer cell function as a clinical assay.Cytometry, , May-01, Volume: 16, Issue:1, 1994
Safety/Toxicity (8)
| Article | Year |
|---|
A flow cytometry based assay that simultaneously measures cytotoxicity and monocyte mediated antibody dependent effector activity.
Journal of immunological methods, , Volume: 462 | 2018 |
Role of monocytes in mediating HIV-specific antibody-dependent cellular cytotoxicity.
Journal of immunological methods, , Oct-31, Volume: 384, Issue:1-2 | 2012 |
CD4(+) CD25(+) FoxP3(+) regulatory T cells suppress cytotoxicity of CD8(+) effector T cells: implications for their capacity to limit inflammatory central nervous system damage at the parenchymal level.
Journal of neuroinflammation, , Feb-28, Volume: 9 | 2012 |
A simplified method for the rapid fluorometric assessment of antibody-dependent cell-mediated cytotoxicity.
Journal of immunological methods, , Jan-20, Volume: 308, Issue:1-2 | 2006 |
Antibody-dependent cell-mediated cytotoxicity: a flow cytometry-based assay using fluorophores.
Journal of immunological methods, , Dec-01, Volume: 258, Issue:1-2 | 2001 |
Development of a novel flow cytometric cell-mediated cytotoxicity assay using the fluorophores PKH-26 and TO-PRO-3 iodide.
Journal of immunological methods, , Jun-01, Volume: 252, Issue:1-2 | 2001 |
Phototoxicity of the fluorescent membrane dyes PKH2 and PKH26 on the human hematopoietic KG1a progenitor cell line.
Cytometry, , Aug-01, Volume: 36, Issue:4 | 1999 |
A novel non-radioactive cellular cytotoxicity test based on the differential assessment of living and killed target and effector cells.
Journal of immunological methods, , Mar-13, Volume: 180, Issue:1 | 1995 |
Interactions (2)